Team says research results show existing safe-in-human broad-spectrum antivirals could be used on other viral infections.
Both partnerships to use Selecta's SVP platform, designed to produce immune tolerance by attenuating the overactive response to specific antigens
Studies show MIPs act as efficient nucleants for hard to crystallize molecules.
Fairjourney Biologics is teaming up with BioRap Technologies and Hadasit Medical Research Services and Development to develop antibodies against the anticancer target heparanase.
$70 million deal covers the E.U, as well as Iceland, Norway, Switzerland and Liechtenstein.
Amunix struck a worldwide research collaboration and licensing deal with Janssen Biotech. Amunix will combine its XTEN half-life extension technology with protein and/or peptide therapeutics selected by Janssen.
If subsequent option periods are all completed, total award value would reach $67 million.
Money is expected to cover 35% of costs to develop 2B3-101 as a treatment for patients whose cancer has metastasized to the brain.
Scientists at the Southwest Foundation for Biomedical Research (SFBR) published their research in the journal PLoS ONE.
Please wait while you are redirected to the right page...